miR-200a-3p Attenuates Coronary Microembolization-Induced Myocardial Injury in Rats by Inhibiting TXNIP/NLRP3-Mediated Cardiomyocyte Pyroptosis

Zhiqing Chen, You Zhou, Feng Chen, Junwen Huang, Haoliang Li, Tao Li, Lang LiFrontiers in Cardiovascular Medicine 2021 · DOI

Abstract

Coronary microembolization (CME) is a frequent complication of percutaneous coronary intervention (PCI), leading to inflammatory myocardial damage. This study identifies miR-200a-3p as a critical regulator that attenuates CME-induced injury by inhibiting the TXNIP/NLRP3-mediated pyroptosis pathway. Overexpression of miR-200a-3p in a rat model significantly improved cardiac function and reduced micro-infarct size, highlighting its potential as a therapeutic target.

Introduction: The Challenge of Coronary Microembolization

Percutaneous coronary intervention (PCI) is essential for treating heart disease, but it can inadvertently cause coronary microembolization (CME). When micro-clots or plaque debris obstruct small distal vessels, they trigger pyroptosis—a highly inflammatory form of programmed cell death. Unlike apoptosis, pyroptosis causes cells to swell and burst, releasing cytokines that damage surrounding healthy tissue.

H&E staining showing a microembolus (arrow) in the CME group.

Methods and Experimental Design

Researchers employed a rat model of CME, inducing micro-clots via the injection of plastic microspheres into the left ventricle. To test the therapeutic potential of miR-200a-3p, an adeno-associated virus (AAV9) was used to overexpress the microRNA four weeks prior to injury. The study utilized a dual-luciferase reporter assay to confirm that miR-200a-3p directly targets the 3′-untranslated region (UTR) of TXNIP (Thioredoxin-interacting protein), a key activator of the NLRP3 inflammasome.

Key Insights: The miR-200a-3p / TXNIP Axis

The study demonstrated that CME causes a sharp decline in miR-200a-3p levels, which normally act as a "brake" on TXNIP. Without this inhibition, TXNIP levels rise, activating the NLRP3 inflammasome. This protein complex then triggers Caspase-1 and Gasdermin D, which punch holes in the cell membrane and lead to the inflammatory explosion of pyroptosis.

Results: Myocardial Protection and Functional Recovery

The induction of CME resulted in significant structural and functional impairment, as evidenced by echocardiography and histology.

Echocardiographic and histological assessment of the rat CME model.

However, rats pre-treated with miR-200a-3p showed remarkable protection:

  • Reduced Infarct Size: Microinfarct area decreased from 14.36% to 5.30% compared to untreated CME rats.
  • Preserved Function: Echocardiography showed that miR-200a-3p treatment significantly maintained Left Ventricular Ejection Fraction (LVEF) and Fractional Shortening (LVFS).
  • Suppressed Inflammation: Serum levels of cardiac biomarkers (cTnI, LDH, CK-MB) and inflammatory cytokines (IL-1β, IL-18) were markedly reduced in treated rats.

Conclusion and Future Directions

The findings define the miR-200a-3p/TXNIP/NLRP3 axis as a major driver of CME-induced injury. While the study utilized a pre-treatment model, it highlights a novel molecular target for preventing myocardial damage during clinical procedures. Future research should focus on post-injury delivery methods and the potential for multi-pathway "cocktail" therapies to further improve outcomes following cardiac interventions.

Summary updated

Abstract

Coronary microembolization (CME) commonly develops as a complication after percutaneous coronary intervention (PCI), and associated inflammation is a leading driver of myocardial damage. Cardiomyocyte loss in the context of ischemic myocardial disease has been linked to inflammatory pyroptotic cell death. Additionally, miR-200a-3p dysregulation has been linked to myocardial ischemia-reperfusion and many other pathological conditions. However, how miR-200a-3p impacts cardiomyocyte pyroptosis in the context of CME remains to be assessed. Herein, a rat model of CME was established via the injection of microembolic spheres into the left ventricle. When myocardial tissue samples from these rats were analyzed, miR-200a-3p levels were markedly decreased, whereas thioredoxin-interacting protein (TXNIP) levels were increased. The ability of miR-200a-3p to directly target TXNIP and to control its expression was confirmed via dual-luciferase reporter assay. Adeno-associated virus serotype 9-pre-miR-200a-3p (AAV-miR-200a-3p) construct transfection was then employed as a means of upregulating this miRNA in CME model rats. Subsequent assays, including echocardiography, enzyme-linked immunosorbent assays (ELISAs), hematoxylin-eosin (H&E) staining, hematoxylin-basic fuchsin-picric acid (HBFP) staining, TdT-mediated dUTP nick-end labeling (TUNEL) staining, immunofluorescence staining, quantitative real-time polymerase chain reaction (qRT-PCR), and Western blotting revealed that miR-200a-3p overexpression inhibited cardiomyocyte pyroptosis and alleviated CME-induced myocardial injury by inhibiting the TXNIP/NOD-like receptor family pyrin domain-containing 3 (NLRP3) pathway. The ability of miR-200a-3p to protect against CME-induced myocardial injury thus highlights a novel approach to preventing or treating such myocardial damage in clinical settings.
BibTeX
@inproceedings{chen2021mir,
  author = {Zhiqing Chen and You Zhou and Feng Chen and Junwen Huang and Haoliang Li and Tao Li and Lang Li},
  title = {{miR-200a-3p Attenuates Coronary Microembolization-Induced Myocardial Injury in Rats by Inhibiting TXNIP/NLRP3-Mediated Cardiomyocyte Pyroptosis}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.693257},
}
Figure